SCHEMBL21409565

SCHEMBL21409565

CCC(c1cccc2ccccc12)c1cccc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
ALDH1A1 P00352 1/20 0.54
CYP1A2 P05177 1/20 0.54
GPR84 Q9NQS5 1/20 0.48
TSHR P16473 1/20 0.45
ACP3 P15309 2/20 0.45
AOC3 Q16853 1/20 0.45
KMT2A Q03164 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12506240 0.92 SLC6A4 (0.65) SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2
SCHEMBL2126034 0.83 ALDH1A1 (0.54) SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2
SCHEMBL15211048 0.81 TSHR (0.55) SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2
SCHEMBL2127427 0.81 TSHR (0.55) SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2
SCHEMBL430798 0.79 CYP2C9 (0.55) SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2
SCHEMBL20691826 0.79 CYP1A2 (0.50) SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2
SCHEMBL3415500 0.79 CYP2C9 (0.50) SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2
SCHEMBL22710196 0.79 ALDH1A1 (0.50) SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2
SCHEMBL22105685 0.79 ALDH1A1 (0.50) SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2
SCHEMBL6680380 0.79 ALDH1A1 (0.61) SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11901249-B2 Curable composition and cured product thereof DIC CORPORATION (JP) 2024-02-13 US disclosed
US-11873356-B2 Curable composition and cured product thereof DIC CORPORATION (JP) 2024-01-16 US disclosed
CN-112119104-B Epoxy (meth) acrylate resin composition, curable resin composition, cured product, and article DIC株式会社 2023-09-29 CN disclosed
CN-111918890-B Curable composition and cured product thereof DIC株式会社 2023-07-07 CN disclosed
WO-2023074258-A1 ACTIVE ESTER COMPOUND 東洋紡株式会社 2023-05-04 WO disclosed
CN-111971323-B Curable composition and cured product thereof DIC株式会社 2023-04-21 CN disclosed
CN-111918891-B Curable composition and cured product thereof DIC株式会社 2023-02-28 CN disclosed
CN-112105661-B Acid group-containing (meth) acrylate resin composition, curable resin composition, cured product, and resin material for solder resist DIC株式会社 2023-02-24 CN disclosed
WO-2023021900-A1 ACTIVE ESTER COMPOUND 東洋紡株式会社 2023-02-23 WO disclosed
US-11548977-B2 Active ester resin and composition and cured product using the same DIC CORPORATION (JP) 2023-01-10 US disclosed
CN-111918891-A Curable composition and cured product thereof DIC株式会社 2020-11-10 CN disclosed
CN-111918890-A Curable composition and cured product thereof DIC株式会社 2020-11-10 CN disclosed
US-20200216603-A1 ACTIVE ESTER RESIN AND COMPOSITION AND CURED PRODUCT USING THE SAME DIC CORPORATION (JP) 2020-07-09 US disclosed
US-20200207700-A1 ACTIVE ESTER COMPOUND AND COMPOSITION AND CURED PRODUCT OBTAINED USING THE SAME DIC CORPORATION (JP) 2020-07-02 US disclosed
CN-110770202-A Active ester resin, and composition and cured product using same DIC株式会社 2020-02-07 CN disclosed
CN-110770203-A Active ester compound, and composition and cured product using same DIC株式会社 2020-02-07 CN disclosed
WO-2019188330-A1 CURABLE COMPOSITION AND CURED PRODUCT OF SAME DIC株式会社 2019-10-03 WO disclosed
WO-2019188332-A1 CURABLE COMPOSITION AND CURED PRODUCT THEREOF DIC株式会社 2019-10-03 WO disclosed
WO-2019188331-A1 CURABLE COMPOSITION AND CURED PRODUCT THEREOF DIC株式会社 2019-10-03 WO disclosed
WO-2019188333-A1 CURABLE COMPOSITION AND CURED PRODUCT THEREOF DIC株式会社 2019-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207700-A1 ACTIVE ESTER COMPOUND AND COMPOSITION AND CURED PRODUCT OBTAINED USING THE SAME CRAT, CYP19A1, EP300 SLC6A4 4823/4885CYP2C9 522/4885CYP2C19 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.